Amanda Dehlendorf, MD
Internal Medicine · Saint Louis, MONPI 1871704270
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 49.6% of the total. 2025 is the largest year on record at $7,524, 3.6 times the $2,090 reported in 2019. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $31.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$7K
- AbbVie$2K
- Amgen$2K
- GSK$651
- Pfizer$554
- Novartis$480
- plus $2K from 19 others
What the payments were for
- Consulting fees$5,20038%
- Travel & lodging$1,1609%
- Food & beverage$7,04952%
- Education$2102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 18 | $6,754 |
| AbbVie | 104 | $2,031 |
| Amgen(2 entities) | 109 | $1,546 |
| GSK | 42 | $651 |
| Pfizer | 40 | $554 |
| Novartis | 25 | $480 |
| Johnson & Johnson(2 entities) | 19 | $419 |
| UCB, Inc. | 19 | $372 |
| Genentech USA, Inc. | 13 | $158 |
| Bristol Myers Squibb | 9 | $151 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Medexus Pharma, Inc. | 4 | $54 |
| Zyla Life Sciences, Inc. | 4 | $52 |
| Sanofi | 2 | $50 |
| Aurinia Pharma U.S., Inc. | 3 | $50 |
| Organon | 2 | $44 |
| Hikma Pharmaceuticals USA | 3 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Tersera Therapeutics LLC | 2 | $28 |
| Assertio Therapeutics, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $13 |
| Iroko Pharmaceuticals, LLC | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$13,620 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 40 | $367,504 |
| Enbrel SureclickEtanercept | 34 | $323,194 |
| RinvoqUpadacitinib | 32 | $267,682 |
| Xeljanz XrTofacitinib Citrate | 21 | $154,344 |
| Orencia ClickjectAbatacept | 11 | $62,419 |
| Hydroxychloroquine Sulfate | 297 | $8,348 |
| Celecoxib | 199 | $7,172 |
| MethotrexateMethotrexate Sodium | 385 | $6,846 |
| Diclofenac Sodium | 45 | $6,141 |
| Tramadol Hcl | 430 | $3,594 |
| Pregabalin | 118 | $3,321 |
| Leflunomide | 110 | $3,050 |
| Prednisone | 688 | $3,022 |
| Mycophenolate Mofetil | 24 | $2,438 |
| Duloxetine Hcl | 124 | $2,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,031 | $267,68232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.